Immuno-Oncology News

November 30, 2020November 30, 2020

Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer

The European Commission has approved Opdivo (nivolumab) as a second-line treatment for adults with advanced inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC), who previously were treated with fluoropyrimidine and ... Read more

November 25, 2020November 25, 2020

Merck Halts Phase 3 Trial on Yervoy-Keytruda Combo in Advanced Lung Cancer

Immuno-Oncology News

Merck has decided to suspend its Phase 3 trial that was assessing a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) as a first-line therapy for patients with advanced non-small cell lung ... Read more

November 23, 2020November 24, 2020

New $100M Program Aims to Improve Diversity in Clinical Trials

Immuno-Oncology News

A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved patient ... Read more

November 20, 2020November 20, 2020

Clinical Trial to Test CRISPR-modified T-cells in Treating Advanced Cancers

Immuno-Oncology News

Immune cells that have been genetically engineered using CRISPR technology will be tested for a first time as a potential treatment of metastatic gastrointestinal cancer in a clinical trial. The Phase 1/2 ... Read more

November 18, 2020November 18, 2020

Phase 3 Study of Epcoritamab for Advanced DLBCL to Open in Europe, Australia

Immuno-Oncology News

Genmab is launching a Phase 3 clinical trial investigating its bispecific antibody epcoritamab as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients who fail to respond ... Read more

November 13, 2020November 13, 2020

Keytruda-Chemo Combo Improves Survival Outcomes in Advanced Lung Cancer

Immuno-Oncology News

First-line treatment with a combination of Keytruda (pembrolizumab) plus chemotherapy significantly prolongs survival, and extends life without disease progression, in people with advanced non-squamous non-small cell lung cancer (NSCLC), regardless ... Read more

November 11, 2020November 11, 2020

Post-surgery Opdivo Found to Reduce Risk of Recurrence in High-risk Bladder Cancer

Immuno-Oncology News

Treatment with Opdivo (nivolumab) after surgery significantly reduces the risk of disease recurrence or death in people with high-risk, muscle-invasive urothelial cancer — a form of bladder cancer — an ... Read more

November 9, 2020November 9, 2020

Opdivo-Yervoy-Chemo Combo Approved in EU for Advanced NSCLC

Immuno-Oncology News

The European Commission has approved a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) plus two cycles of platinum-based chemotherapy as a first-line treatment for people with advanced non-small cell lung cancer (NSCLC) ... Read more

November 6, 2020November 6, 2020

Tecentriq-Avastin Combo Approved in Europe for Advanced or Inoperable Liver Cancer

Immuno-Oncology News

The European Commission has approved the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for adults with advanced or inoperable hepatocellular carcinoma (HCC), the most common form ... Read more

November 2, 2020November 2, 2020

Libtayo Given FDA Priority Review for Advanced NSCLC With High PD-L1 Levels

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has granted priority review to an application seeking the approval of Libtayo (cemiplimab) as a first-line therapy for advanced non-small cell lung cancer (NSCLC) and high PD-L1 levels, according ... Read more

October 30, 2020October 30, 2020

Nearly Half of Imfinzi-treated NSCLC Patients Alive After 4 Years, PACIFIC Update Shows

Immuno-Oncology News

Imfinzi (durvalumab) continues to demonstrate a sustained survival benefit in patients with inoperable, locally advanced non-small cell lung cancer (NSCLC) who had not progressed after platinum-based chemotherapy and radiation therapy, a ... Read more

October 28, 2020October 28, 2020

Opdivo Combo Found to Extend Survival in Advanced Stomach, Esophageal Cancers

Immuno-Oncology News

Adding Opdivo (nivolumab) to standard first-line chemotherapy significantly extends overall survival and delays disease progression or death in adults with inoperable advanced HER2-negative stomach cancer, esophageal adenocarcinoma, or gastroesophageal junction (GEJ) cancer, ... Read more

October 26, 2020October 26, 2020

Opdivo-Cabometyx Granted FDA Priority Review for Newly Diagnosed Advanced Kidney Cancer

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has agreed to review applications requesting the approval of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) for people with advanced renal cell cancer, the most common type of ... Read more

October 23, 2020October 23, 2020

Cancer Vaccine UV1 Plus Keytruda Shows Safety, Early Efficacy in Advanced Melanoma Trial

Immuno-Oncology News

Adding UV1, Ultimovacs’ experimental cancer vaccine, to Keytruda (pembrolizumab) is safe and shows initial signs of effectiveness in adults with previously untreated metastatic melanoma, according to top-line data from a Phase 1 ... Read more

October 21, 2020October 21, 2020

Committee Recommends EU Approval of Opdivo to Treat Advanced Esophageal Cancer

Immuno-Oncology News

A committee of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the treatment of people with advanced, inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who ... Read more